)
Visual24 Oct 2025
The rise of Alphabet
Heartbeam (BEAT) investor relations material
Heartbeam Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary13 Aug, 2025
Executive summary
Achieved FDA 510(k) clearance for a portable, cable-free ECG system in December 2024, with 12-lead synthesis software clearance expected by end of 2025; pivotal study showed 93.4% diagnostic agreement with standard ECGs.
Commercial readiness efforts include hardware/software enhancements, infrastructure buildout, and engagement with concierge and preventive cardiology practices in Florida and Southern California.
Early access and beta programs, plus strategic collaborations (e.g., AccurKardia), have informed product improvements and business model validation.
Strong and increasing interest from industry partners and strategic players as regulatory clearance and commercialization approach.
Expanded intellectual property portfolio to 21 issued patents worldwide and received multiple industry recognitions, including Innovation in Remote Cardiac Diagnostics.
Financial highlights
Net cash used in operating activities was $3.4M for Q2 2025, a 23% decrease from the previous quarter; cash and short-term investments totaled $5.1M at June 30, 2025.
Baseline recurring expenditure was $3.1M, 11% lower than the historic baseline; investments in commercial readiness and manufacturing totaled ~$0.3M.
Net loss for Q2 2025 was $5.0M, unchanged from Q2 2024; operating expenses for Q2 2025 were $5.0M, slightly down year-over-year.
General and administrative expenses decreased, while R&D expenses increased year-over-year for Q2 2025.
No material commercial revenue expected in 2025; continued negative cash flow from operations.
Outlook and guidance
FDA clearance for 12-lead ECG synthesis software remains on track for Q4 2025, with commercial launch to begin immediately after clearance.
Additional FDA submission for arrhythmia assessment algorithm and MI pilot study enrollment expected in Q4.
Management expects existing liquidity to be insufficient for the next twelve months, raising substantial doubt about going concern status; plans to raise additional capital.
Ongoing focus on capital efficiency, disciplined spending, and minimizing shareholder dilution while funding key milestones.
Commercial readiness plans include cardiology reader service and logistics infrastructure.
Discuss timeline for AccurKardia FDA submission.
Detail plans for managing potential dilution.
Describe likely strategic partner types.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Heartbeam earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
HeartBeam, Inc. is a medical technology company focused on developing innovative cardiac care solutions. The company’s primary product is a proprietary 3D-vector ECG platform designed to assist in the detection and diagnosis of heart attacks and other cardiac conditions. HeartBeam aims to provide more accurate and accessible cardiac care tools, enabling healthcare professionals to monitor and diagnose heart-related issues in both clinical and remote settings. The company serves the healthcare industry, particularly in the fields of cardiology and emergency medicine, with a focus on improving diagnostic accuracy and patient outcomes. The company is headquartered in Santa Clara, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage